A survey has indicated that only 22.5% of practitioners follow the recommended protocol for treating headaches with botulinum toxin.
The London Academy of Aesthetic Medicine has launched The Online Ultimate Toxin Course.
In December, global pharmaceutical company Allergan celebrated the beginning of the 30th anniversary celebration for Botox with the ringing of the New York Stock Exchange opening bell.
US-based medical aesthetic company Evolus Inc has begun a consumer campaign in the US called ‘#NEWTOX NOW’ in the hope to encourage patients to use its botulinum toxin.
The results of two studies conducted by pharmaceutical company Galderma (UK) Limited have demonstrated high patient satisfaction for the use of Azzalure (AbobotulinumtoxinA), its botulinum toxin type A product, in the glabellar complex.
On June 17 Aesthetics Media will be hosting its second webinar in association with pharmaceutical company Galderma UK.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the marketing authorisation application for Evolus’ botulinum toxin type A formulation.
Global pharmaceutical company Galderma will host two Masterclasses at ACE 2019.
The Food and Drug Administration (FDA) has approved Jeuveau, a botulinum toxin type A, for the temporary improvement in the appearance of moderate to severe glabellar lines.
A clinical study conducted by global pharmaceutical company Allergan suggests that higher doses of Botox Cosmetic (onabotulinumtoxinA) to treat moderate to severe glabella lines produces greater duration of treatment effect.